COVID-19 Treatment, Testing Costs Could Reach $417 Billion Over Next Year

With the novel coronavirus spreading across the nation, both private health insurers and public payers could see heavy economic costs. According to a recent paper prepared by Wakely Consulting Group on behalf of America’s Health Insurance Plans, under the baseline risk scenario with a U.S. infection rate of 20%, allowed costs could range from $112.5 billion to $185.4 billion over 2020 and 2021 combined. As the ultimate number and severity of COVID-19 cases remain unknown, the estimates have a wide range. Graphics below highlight three different organizations’ estimates for how the pandemic will change U.S. health care costs.

0 Comments
© 2021 MMIT

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_321525828.jpg
November 24

‘Long COVID’ Presents Big Challenges for Health Plans, Patients

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-Pathway-or-Perish-The-Two-Pronged-Hurdle-to-Ensuring-Access-in-Oncology.jpg
November 24

Insurers Applaud New CMMI Push for Risk-Based Contracting

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_176559451.jpg
November 24

Non-Emergent 911 Calls Offer Intervention Opportunity

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today